Mayo Clinic Multiple Myeloma SPORE

项目摘要/摘要 梅奥诊所多发性骨髓瘤孢子(孢子)是一项动态、多产、可转化的癌症研究 基于所有三个梅奥诊所站点(罗切斯特明尼苏达州，佛罗里达州杰克逊维尔，凤凰城亚利桑那州)的计划，现在有来自 安大略省多伦多的玛格丽特公主癌症中心。2003-2013年间，我们参加了联合 DFCI/Mayo诊所多发性骨髓瘤孢子，自2015年以来在Mayo诊所多发性骨髓瘤孢子。在… 孢子的持续成功的中心是调查人员之间的合作互动 在整个梅奥基金会，以及孢子基础实验室、翻译和临床调查人员 和专注于MM的患者倡导者。孢子的总体目标是支持创新、互动、 严格的翻译骨髓瘤研究，利用实验室、翻译和临床的专业知识 专业知识。在过去的资助期内，孢子的产量很高，如下所示 鉴定临床上正在使用的新的肿瘤标志物和预后指数；科学发现 领导了孢子内外的创新临床试验；多篇出版物，其中许多由 来自多个地点的研究人员；以及转化性临床试验的活跃收益。该孢子参与了 与其他国家和国际学术机构开展多项富有成效的纵向和横向合作 机构和组织。例如，在以患者为中心的临床试验中领导临床工作 来自多发性骨髓瘤研究基金会、国际骨髓瘤基金会和骨髓瘤皇冠。这个 目前的提案包括3个主要研究项目。根据研究结果，其中两个项目是新的 在过去供资期间获得的，而项目1是继续努力，以调查 调节免疫微环境提高I期MM溶瘤病毒治疗的疗效 临床试验。项目2是对高危多发性骨髓瘤的综合多组学分析和高度相关的临床试验。 重点是在这组患者中找出没有从最近的 预付款。项目3正在研究遗传性和微环境疾病进展的机制 阴燃MM到MM，以便及早发现需要治疗的MM。该孢子还包括 发展研究和职业提升计划在MM中追求新的翻译概念 研究人员和新调查人员分别通过这两个项目。最后，孢子会增强 通过管理部门中的共享核心资源支持翻译MM研究的基础设施， 生物统计学与生物信息学、生物谱学与临床数据库。

PROJECT SUMMARY/ABSTRACT The Mayo Clinic Multiple Myeloma SPORE (SPORE) is a dynamic, productive, translational cancer research program based at all three Mayo Clinic sites (Rochester MN, Jacksonville FL, Phoenix AZ), now with input from the Princess Margaret Cancer Centre in Toronto, Ontario. From 2003-2013 we participated in the joint DFCI/Mayo Clinic Multiple Myeloma SPORE, and since 2015 in the Mayo Clinic Multiple Myeloma SPORE. At the center of the ongoing success of the SPORE is the collaborative interaction between investigators throughout the Mayo Foundation, as well as SPORE basic laboratory, translational and clinical investigators and patient advocates focused on MM. The overall goal of the SPORE is to support innovative, interactive, rigorous translational myeloma research that leverages the expertise of laboratory, translational and clinical expertise. Over the last funding period, the SPORE has been highly productive as demonstrated by identification of new tumor markers and prognostic indices that are being used clinically; scientific findings that led to innovative clinical trials both within and outside the SPORE; multiple publications with many authored by investigators from multiple sites; and brisk accrual to translational clinical trials. The SPORE was involved in multiple productive vertical and horizontal collaborations with other national and international academic institutions and organizations. For example, with leadership of clinical efforts in patient-focused clinical trials from the Multiple Myeloma Research Foundation, International Myeloma Foundation, and MyelomaCrowd. The current proposal includes 3 major research projects. Two of the projects are new, based on research results obtained over the past funding period, while Project 1 is a continuation of efforts to investigate ways of modulating the immune micro-environment to improve the efficacy of oncolytic viral therapy in MM in a phase I clinical trial. Project 2 is an integrated multi-omic analysis of high-risk MM with associated clinical trial highly focused on identifying promising approaches in this group of patients that have not benefited from recent advances. Project 3 is investigating the genetic and microenvironmental mechanisms of progression of smoldering MM to MM to enable early detection of MM requiring treatment. The SPORE also includes Developmental Research and Career Enhancement Programs to pursue novel translational concepts in MM research and new investigators through the programs respectively. Finally, the SPORE will enhance the infrastructure that supports translational MM research through shared core resources in Administration, Biostatistics & Bioinformatics, and Biospecimens & Clinical Database.